{
  "nct_id": "NCT20848327",
  "indication": "Rheumatoid Arthritis",
  "phase": "Phase 3",
  "sample_size": 836,
  "duration_weeks": 21,
  "dropout_rate": 0.15,
  "blinding": "open-label",
  "control_arm": "active comparator",
  "primary_endpoints": [
    "ACR20 response"
  ],
  "secondary_endpoints": [
    "HAQ-DI improvement",
    "DAS28 score reduction"
  ],
  "outcome_summary": "Demonstrated superior efficacy compared to placebo",
  "success": 1,
  "start_date": "2021-08-20",
  "completion_date": "2022-01-14"
}